Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 Jun 24, 385:113979.

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 Jun 24, 385:113979.  PMID: 40570966

• This study highlights the pivotal role of QS-21, a potent saponin adjuvant, in enhancing the immunogenicity and therapeutic efficacy of the engineered hybrid membrane vesicles. 
• By incorporating QS-21 into the vaccine platform, along with a structurally simplified TLR4 agonist GAP-112, the researchers achieved a synergistic stimulation of innate immune responses, including increased cytokine production and activation of antigen-presenting cells. QS-21 notably contributed to the induction of robust antibody production and T cell responses, thereby amplifying the vaccine’s capacity to elicit potent anti-tumor immunity in multiple tumor models. Its inclusion not only enhanced antigen uptake and immune activation but also supported the development of long-lasting immune memory, underscoring its critical function in the design of effective cancer vaccines
• These findings underscore the potential of QS-21 to improve the efficacy and safety of cancer immunotherapies, positioning it as an essential component in the development of versatile and effective vaccine platforms.

Click here to access the full scientific paper.